Abstract:The existence of eosinophils was documented histopathologically in the first half of the 19th century. However, the term "eosinophils" was first used by Paul Ehrlich in 1878. Since their discovery and description, their existence has been associated with asthma, allergies, and antihelminthic immunity. Eosinophils may also be responsible for various possible tissue pathologies in many eosinophil-associated diseases. Since the beginning of the 21st century, the understanding of the nature of this cell population has undergone a fundamental reassessment, and in 2010, J. J. Lee proposed the concept of "LIAR" (Local Immunity And/or Remodeling/Repair), underlining the extensive immunoregulatory functions of eosinophils in the context of health and disease. It soon became apparent that mature eosinophils (in line with previous morphological studies) are not structurally, functionally, or immunologically homogeneous cell populations. On the contrary, these cells form subtypes characterized by their further development, immunophenotype, sensitivity to growth factors, localization, role and fate in tissues, and contribution to the pathogenesis of various diseases, including asthma. The eosinophil subsets were recently characterized as resident (rEos) and inflammatory (iEos) eosinophils. During the last 20 years, the biological therapy of eosinophil diseases, including asthma, has been significantly revolutionized. Treatment management has been improved through the enhancement of treatment effectiveness and a decrease in the adverse events associated with the formerly ultimately used systemic corticosteroids. However, as we observed from real-life data, the global treatment efficacy is still far from optimal. A fundamental condition, "sine qua non", for correct treatment management is a thorough evaluation of the inflammatory phenotype of the disease. We believe that a better understanding of eosinophils would lead to more precise diagnostics and classification of asthma subtypes, which could further improve treatment outcomes. The currently validated asthma biomarkers (eosinophil count, production of NO in exhaled breath, and IgE synthesis) are insufficient to unveil super-responders among all severe asthma patients and thus give only a blurred picture of the adepts for treatment. We propose an emerging approach consisting of a more precise characterization of pathogenic eosinophils in terms of the definition of their functional status or subset affiliation by flow cytometry. We believe that the effort to find new eosinophil-associated biomarkers and their rational use in treatment algorithms may ameliorate the response rate to biological therapy in patients with severe asthma.

Severe eosinophilic asthma: a roadmap to consensus

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetings

Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline

Different endotypes and phenotypes drive the heterogeneity in severe asthma

Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons

Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?

Characteristics, phenotypes, mechanisms and management of severe asthma

Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI)

Phenotyping of Severe Asthma in the Era of Broad-acting Anti-asthma Biologics

Emerging Biologics in Severe Asthma

Chinese expert consensus on diagnosis and management of severe asthma

Eosinophils Target Therapy for Severe Asthma: Critical Points

Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)

Asthma Endotypes and an Overview of Targeted Therapy for Asthma

Exploring novel perspectives on eosinophilic inflammation in severe asthma

Diagnosis and management of eosinophilic asthma: a US perspective

Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment

Barriers to clinical remission in severe asthma

Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice

Clinical remission and control in severe asthma: agreements and disagreements